Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

281
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
281
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

247
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
247
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

200
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
200
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

229
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
229
Hepatic Portal System01:21

Hepatic Portal System

5.9K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
5.9K
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

583
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
583

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Endoscopic treatment modalities for colonic diverticular bleeding: A systematic review with direct and network meta-analyses.

World journal of gastrointestinal endoscopy·2025
Same author

Comprehensive Clinicopathologic, Morphologic, and Molecular Evaluation and Outcomes in Polymorphous Adenocarcinoma Tumors With Applicability of a 2-Tiered Grading System.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2025
Same author

Gender disparities and woman-specific trends in Barrett's esophagus in the United States: An 11-year nationwide population-based study.

World journal of methodology·2025
Same author

Statins decrease the risk of hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease: A systematic review and meta-analysis.

World journal of experimental medicine·2024
Same author

Early versus delayed necrosectomy in pancreatic necrosis: A population-based cohort study on readmission, healthcare utilization, and in-hospital mortality.

World journal of methodology·2024
Same author

Long-term outcomes of catheter ablation for atrial fibrillation in octogenarians.

Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing·2024
Same journal

Immunohistochemistry (IHC) Versus Genomic Profiling in Cancer: Roles in Precision Medicine.

Cureus·2026
Same journal

Pediatric Nasal Tip Reconstruction After a Donkey Bite Using an Expanded Paramedian Forehead Flap With Conchal Cartilage Grafts: A Case Report.

Cureus·2026
Same journal

Splenic Rupture: A Delayed and Rare Complication of Colonoscopy.

Cureus·2026
Same journal

Super-refractory Status Epilepticus in Febrile Infection-Related Epilepsy Syndrome Triggered by Influenza A: A Pediatric Case Report.

Cureus·2026
Same journal

Comparative Evaluation of Serum Peroxiredoxin 2 (PRDX2), Serum Peroxiredoxin 4 (PRDX4), and Plasma Methylated Septin 9 (mSEPT9) Levels Against Conventional Biomarkers for Early Detection of Colorectal Cancer: A Study Protocol.

Cureus·2026
Same journal

Inspiratory Muscle Training for Patients With Chronic Obstructive Pulmonary Disease: A Narrative Review.

Cureus·2026
See all related articles

Related Experiment Video

Updated: Feb 1, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

853

Lafora Disease Masquerading as Hepatic Dysfunction.

Faisal Inayat1, Waqas Ullah2, Hanan T Lodhi3

  • 1Internal Medicine, Allama Iqbal Medical College, Lahore, PAK.

Cureus
|December 1, 2018
PubMed
Summary
This summary is machine-generated.

Lafora disease, a fatal epilepsy, can initially present with elevated liver enzymes in asymptomatic individuals. Early liver biopsy and genetic testing are crucial for timely diagnosis and intervention.

Keywords:
hepatic dysfunctionlafora diseaseunusual presentation

More Related Videos

Mapping Dysfunctional Protein-Protein Interactions in Disease
09:39

Mapping Dysfunctional Protein-Protein Interactions in Disease

Published on: October 24, 2025

820
Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
07:03

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

1.8K

Related Experiment Videos

Last Updated: Feb 1, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

853
Mapping Dysfunctional Protein-Protein Interactions in Disease
09:39

Mapping Dysfunctional Protein-Protein Interactions in Disease

Published on: October 24, 2025

820
Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
07:03

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

1.8K

Area of Science:

  • Neurology
  • Hepatology
  • Genetics

Background:

  • Lafora disease is a fatal, progressive myoclonic epilepsy.
  • Typically presents in late childhood/adolescence with seizures, ataxia, and dementia.

Observation:

  • An asymptomatic young male soccer player presented with elevated liver enzymes.
  • Extensive workup for common liver diseases was inconclusive.

Findings:

  • Percutaneous liver biopsy revealed pathognomonic histopathological findings.
  • Lafora disease was identified as the likely etiology based on biopsy results.

Implications:

  • This case highlights Lafora disease presenting initially with hepatic dysfunction.
  • Emphasizes the importance of considering Lafora disease in unexplained liver enzyme abnormalities.
  • Suggests prompt liver biopsy and genetic testing to enable early diagnosis and intervention.